{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:40:55Z","timestamp":1783708855779,"version":"3.55.0"},"reference-count":44,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Aims\u2003The efficacy and safety of aspirin for primary cardiovascular disease (CVD) prevention is controversial. The aim of this study was to investigate the efficacy and safety of aspirin in subjects with no overt CVD, with a focus on age as a treatment modifier.<\/jats:p><jats:p>\n          Methods and Results\u2003Randomized trials comparing aspirin use versus no aspirin use or placebo were included. The primary efficacy outcome was all-cause death. The primary safety outcome was major bleeding. Secondary ischemic and bleeding outcomes were explored. Subgroup analyses were conducted to investigate the consistency of the effect sizes in studies including younger and older individuals, using a cut-off of 65 years. A total of 21 randomized trials including 173,810 individuals at a mean follow-up of 5.3 years were included. Compared with control, aspirin did not reduce significantly the risk of all-cause death (risk ratio: 0.96; 95% confidence interval: 0.92\u20131.00, p\u2009=\u20090.057). Major adverse cardiovascular events were significantly reduced by 11%, paralleled by significant reductions in myocardial infarction and transient ischemic attack. Major bleeding, intracranial hemorrhage, and gastrointestinal bleeding were significantly increased by aspirin. There was a significant age interaction for death (p for interaction\u2009=\u20090.007), with aspirin showing a statistically significant 7% relative benefit on all-cause death in studies including younger patients.<\/jats:p><jats:p>\n          Conclusion\u2003The use of aspirin in subjects with no overt CVD was associated with a neutral effect on all-cause death and a modest lower risk of major cardiovascular events at the price of an increased risk in major bleeding. The benefit of aspirin might be more pronounced in younger individuals.<\/jats:p>","DOI":"10.1055\/a-1667-7427","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T03:58:48Z","timestamp":1634097528000},"page":"445-455","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies"],"prefix":"10.1055","volume":"122","author":[{"given":"Dario","family":"Calderone","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Ingala","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agnello","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Franchina","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scalia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Buccheri","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u201cG. Rodolico \u2013 San Marco\u201d University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,12,31]]},"reference":[{"issue":"11","key":"ref1","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"D K Arnett","year":"2019","journal-title":"Circulation"},{"issue":"29","key":"ref2","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"M F Piepoli","year":"2016","journal-title":"Eur Heart J"},{"issue":"34","key":"ref3","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"F LJ Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14779072.2019.1651199","article-title":"Aspirin for the primary prevention of cardiovascular disease: latest evidence","volume":"17","author":"D Capodanno","year":"2019","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"J M Gaziano","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"ref6","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"L Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"ref7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"J J McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"ref8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"J J McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"J J McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"ref10","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"73","author":"H K Abdelaziz","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"S L Zheng","year":"2019","journal-title":"JAMA"},{"issue":"16","key":"ref12","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMe1812000","article-title":"Should aspirin be used for primary prevention in the post-statin era?","volume":"379","author":"P M Ridker","year":"2018","journal-title":"N Engl J Med"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","article-title":"Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"40","author":"A N Mahmoud","year":"2019","journal-title":"Eur Heart J"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"S Yusuf","year":"2021","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.296.6618.313","article-title":"Randomised trial of prophylactic daily aspirin in British male doctors","volume":"296","author":"R Peto","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians' Health Study","volume":"321","author":"Steering Committee of the Physicians' Health Study Research Group","year":"1989","journal-title":"N Engl J Med"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results","volume":"54","author":"B Farrell","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.1992.03490100090033","article-title":"Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14. ETDRS Investigators","volume":"268","year":"1992","journal-title":"JAMA"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-123-9-199511010-00002","article-title":"Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing","volume":"123","author":"R C\u00f4t\u00e9","year":"1995","journal-title":"Ann Intern Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council's General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project","volume":"357","author":"G de Gaetano","year":"2001","journal-title":"Lancet"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"R Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"23","key":"ref23","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial","volume":"312","author":"Y Ikeda","year":"2014","journal-title":"JAMA"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial","volume":"135","author":"Y Saito","year":"2017","journal-title":"Circulation"},{"issue":"23","key":"ref25","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A critical appraisal of aspirin in secondary prevention: is less more?","volume":"134","author":"G Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"M Valgimigli","year":"2021","journal-title":"BMJ"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"D Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"L Li","year":"2017","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fphar.2010.00126","article-title":"Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes","volume":"1","author":"L Cea Soriano","year":"2010","journal-title":"Front Pharmacol"},{"key":"ref31","first-page":"8S","article-title":"Aging, the gastrointestinal tract, and risk of acid-related disease","volume":"117","author":"D A Greenwald","year":"2004","journal-title":"Am J Med"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10143-004-0337-6","article-title":"Demographics and prevalent risk factors of chronic subdural haematoma: results of a large single-center cohort study","volume":"27","author":"H Baechli","year":"2004","journal-title":"Neurosurg Rev"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/2152-7806.104744","article-title":"Chronic subdural hematomas and the elderly: surgical results from a series of 125 cases: old \u201chorses\u201d are not to be shot!","volume":"3","author":"D O de Ara\u00fajo Silva","year":"2012","journal-title":"Surg Neurol Int"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaneurol.2019.1120","article-title":"Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis","volume":"76","author":"W-Y Huang","year":"2019","journal-title":"JAMA Neurol"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","article-title":"The multifaceted clinical readouts of platelet inhibition by low-dose aspirin","volume":"66","author":"C Patrono","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2016.05.083","article-title":"Aspirin and cancer","volume":"68","author":"P Patrignani","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cct.2016.10.004","article-title":"ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours","volume":"51","author":"C Coyle","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"L Hansson","year":"1998","journal-title":"Lancet"},{"issue":"13","key":"ref39","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"P M Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2796.2006.01763.x","article-title":"Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial","volume":"261","author":"M Catalano","year":"2007","journal-title":"J Intern Med"},{"issue":"07","key":"ref41","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"D Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"J Belch","year":"2008","journal-title":"BMJ"},{"issue":"09","key":"ref43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jama.2010.221","article-title":"Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial","volume":"303","author":"F GR Fowkes","year":"2010","journal-title":"JAMA"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-018-6802-1","article-title":"Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER study)","volume":"32","author":"M Goicoechea","year":"2018","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1667-7427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T14:47:55Z","timestamp":1660142875000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1667-7427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":44,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2022,3,4]]},"published-print":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1667-7427","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,12]]},"published":{"date-parts":[[2021,10,12]]}}}